|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/4155 | |
| A61K 31/4166 | |||
| A61K 45/06 | |||
| A61K 31/58 | |||
| A61P 35/00 | |||
| A61P 35/02 |
| (11) | Number of the document | 3052098 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14790344.7 |
| Date of filing the European patent application | 2014-10-01 | |
| (97) | Date of publication of the European application | 2016-08-10 |
| (45) | Date of publication and mention of the grant of the patent | 2020-12-02 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/IB2014/064997 |
| Date | 2014-10-01 |
| (87) | Number | WO 2015/049650 |
| Date | 2015-04-09 |
| (30) | Number | Date | Country code |
| 201361885053 P | 2013-10-01 | US | |
| 201461935404 P | 2014-02-04 | US |
| (72) |
CORNFELD, Mark J., US
KUMAR, Rakesh, US
MORRIS, Shannon Renae, US
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | ENZALUTAMIDE IN COMBINATION WITH AFURESERTIB FOR THE TREATMENT OF PROSTATE CANCER |
| ENZALUTAMIDE IN COMBINATION WITH AFURESERTIB FOR THE TREATMENT OF PROSTATE CANCER |